PVLA · NASDAQ
Palvella Therapeutics (PVLA) Stock Price & Fundamentals
Palvella Therapeutics (PVLA) closed at $730.48 on Oct 9, 2026, down 0.55% from the previous close of $734.54.
Share price, past year
1Y +6.72%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $730.48 |
| Sep 30, 2026 | $748.96 |
| Aug 31, 2026 | $708.66 |
| Jul 31, 2026 | $733.05 |
| Jun 30, 2026 | $746.46 |
| May 29, 2026 | $661.05 |
| Apr 30, 2026 | $627.82 |
| Mar 31, 2026 | $646.23 |
| Feb 27, 2026 | $632.58 |
| Jan 30, 2026 | $697.29 |
| Dec 31, 2025 | $689.32 |
| Nov 28, 2025 | $715.12 |
| Oct 31, 2025 | $706.88 |
Key statistics
- Market cap
- $10.52B
- P/E (TTM)
- —
- EPS (TTM)
- −$4.83
- Revenue (TTM)
- —
- Net income (TTM)
- −$61.70M
- Shares outstanding
- 14.4M
- Dividend yield
- —
- 52-week range
- $616.46 – $749.52
Palvella Therapeutics's market cap is $10.52B, based on a share price of $730.48 and 14.4M shares outstanding as of Jun 30, 2026.
Financials
Palvella Therapeutics reported revenue of $42.81M for fiscal 2023, up 65.28% from fiscal 2022.
Palvella Therapeutics reported a net loss of $41.72M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2023ended Dec 31, 2023 | $42.81M | +65.3% | $18.69M | 43.7% | $2.17 | −$13.87M |
| FY2022ended Dec 31, 2022 | $25.90M | −17.6% | −$33.28M | −128.5% | — | −$60.97M |
| FY2021ended Dec 31, 2021 | $31.42M | +7.1% | −$45.74M | −145.6% | −$0.71 | −$8.61M |
| FY2020ended Dec 31, 2020 | $29.32M | −36.6% | −$37.23M | −127.0% | −$0.68 | −$48.62M |
| FY2019ended Dec 31, 2019 | $46.28M | +59.0% | −$25.47M | −55.0% | −$0.56 | −$54.93M |
| FY2018ended Dec 31, 2018 | $29.10M | +15.1% | −$26.75M | −91.9% | −$0.50 | −$2.76M |
| FY2017ended Dec 31, 2017 | $25.28M | +333.5% | −$17.65M | −69.8% | −$0.40 | $47.80M |
| FY2016ended Dec 31, 2016 | $5.83M | +98.9% | −$22.80M | −391.0% | −$0.55 | — |
| FY2015ended Dec 31, 2015 | $2.93M | — | — | — | −$0.41 | — |
| FY2014ended Jun 30, 2014 | $0.00 | — | — | — | — | −$15.06K |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$6.78M | −$3.94 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
| Q1 FY2024ended Mar 31, 2024 | $53.00K | — | — |
| Q4 FY2023ended Dec 31, 2023 | $1.30M | — | — |
| Q3 FY2023ended Sep 30, 2023 | $19.52M | — | — |
| Q2 FY2023ended Jun 30, 2023 | $20.06M | — | — |
| Q1 FY2023ended Mar 31, 2023 | $1.94M | — | — |
| Q4 FY2022ended Dec 31, 2022 | $5.85M | — | — |
Company profile
- Name
- Palvella Therapeutics, Inc.
- Ticker
- PVLA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 353 W. Lancaster Avenue, Suite 200, Wayne, PA 19087
- Incorporated in
- NV
- Fiscal year ends
- December
- SEC CIK
- 0001583648
Recent SEC filings
- Aug 4, 2026
- Aug 4, 2026
- Jul 14, 2026
- Jun 30, 2026
- Jun 16, 2026
- May 20, 2026
- May 15, 2026
- May 13, 2026
Frequently asked questions
What is Palvella Therapeutics's stock price?
Palvella Therapeutics (PVLA) closed at $730.48 on Oct 9, 2026, down 0.55% from the previous close of $734.54.
What is Palvella Therapeutics's market cap?
Palvella Therapeutics's market cap is $10.52B, based on a share price of $730.48 and 14.4M shares outstanding as of Jun 30, 2026.
How much revenue does Palvella Therapeutics make?
Palvella Therapeutics reported revenue of $42.81M for fiscal 2023, up 65.28% from fiscal 2022.
Does Palvella Therapeutics pay a dividend?
Palvella Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Palvella Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures